Galectin Role in Periodontal Disease

Not Applicable

Completed

• Conditions: Gingivitis; Periodontitis
• Interventions: Diagnostic Test: GCF sample collection; Procedure: non-surgical periodontal treatment

• Registration Number: NCT06038812
• Lead Sponsor: Fayoum University

Brief Summary

This study aimed at exploring the effect of nonsurgical periodontal treatment on galectin 1 and 3 GCF levels in patients having gingivitis, periodontitis stage III compared to periodontally healthy individuals and if galectin-1 and -3 could serve as diagnostic markers and/or therapeutic targets for periodontitis, in addition to revealing their possible role in the periodontal disease.

45 systemically healthy participants were enrolled in this investigation, equally subdivided into three groups of 15 patients each: gingivitis, periodontitis (stage III) and control group with healthy gingiva. Probing depth, clinical attachment level, gingival and plaque index were registered. GCF levels of galectin-1 and -3 were evaluated in all included groups (before and after non-surgical treatment for periodontitis group) using enzyme linked immune-sorbent assay (ELISA) kit.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-08-01
• Study First Submitted: 2023-08-30
• Study First Submitted QC: 2023-09-14
• Study First Posted: 2023-09-15
• Primary Completion: 2023-09-30
• Study Completion: 2023-09-30
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-11
• Last Update Posted: 2024-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

1. Non-smokers from both genders.
2. Not suffering from systemic diseases, pregnancy/lactation.
3. Not taking contraceptive pills, antibiotics, anti-inflammatory, or immunosuppressive drugs before inclusion in the study by 6 months.
4. Patients with only gingivitis or periodontitis stage III.
5. Periodontitis patients who did not receive any professional periodontal treatment in the last 6 months.

Exclusion Criteria

1. smokers.
2. having systemic diseases, pregnancy/lactation.
3. taking contraceptive pills, antibiotics, anti-inflammatory, or immunosuppressive drugs in the past 6 months.
4. Patients having periodontitis any other stage than stage III.
5. Periodontitis patients who receive any professional periodontal treatment in the last 6 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group II	GCF sample collection	patients diagnosed with periodontitis
Group II	non-surgical periodontal treatment	patients diagnosed with periodontitis
Group III	GCF sample collection	healthy control
Group I	GCF sample collection	patients diagnosed with gingivitis

Primary Outcome Measures

Name	Time	Method
assessment of gal-1 and gal-3 in GCF samples	an average of about 10 months to assess level of gal-1 & -3 after collection of GCF samples at baseline (1st appointment) for all groups and another sample collection after 4 weeks for group II after performing scaling and root planning	samples are to be sent to biochemistry lab to measure galectin levels

Trial Locations

Locations (1)

faculty of dentistry, Fayoum university; 🇪🇬 Fayoum, Egypt